4-fluoro-N-methylpyridin-2-amine | 1260832-12-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-fluoro-N-methylpyridin-2-amine
• CAS: 1260832-12-9
• 化学式: C₆H₇FN₂
• 分子量: 126.133
• InChiKey: IPJOPPLKZMQQSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-fluoro-N-methylpyridin-2-amine 在 N-碘代丁二酰亚胺 作用下， 以 乙腈 为溶剂， 以450 mg的产率得到4-fluoro-5-iodo-N-methylpyridin-2-amine
  参考文献：
  名称：

  WO2023/129513

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl N-(4-fluoro-2-pyridyl)-N-methylcarbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-fluoro-N-methylpyridin-2-amine
  参考文献：
  名称：

  WO2023/129513

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：IRM LLC

  公开号：WO2014078813A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.

  本发明提供了式I的化合物：[在此插入公式]或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物以及使用这种化合物治疗、预防、抑制、改善或根除由疟原虫引起的疟疾等疾病的方法。
• Azaquinazoline Inhibitors Of Atypical Protein Kinase C
  申请人：Ignyta, Inc.

  公开号：US20150274720A1

  公开（公告）日：2015-10-01

  The present application provides a compound of formula (I) and/or a salt thereof, wherein R 1 , G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.

  本申请提供了一种具有化学式（I）的化合物和/或其盐，其中R1、G和X如本文所定义。化合物的化学式（I）和/或其盐具有aPKC抑制活性，并可用于治疗增生性疾病。还提供了包含化学式（I）的化合物和/或其盐的组合物。
• In situ click chemistry method for screening high affinity molecular imaging probes
  申请人：Kolb C. Hartmuth

  公开号：US20060269942A1

  公开（公告）日：2006-11-30

  The invention provides a method for identifying a candidate imaging probe, the method comprising: a) contacting a first library of candidate compounds with a target biomacromolecule, b) identifying a first member from the first library exhibiting affinity for the first binding site; c) contacting the first member identified from the first library affinity for the first binding site with the target biomacromolecule; d) contacting a second library of candidate compounds with the first member and the target biomacromolecule, e) reacting the complementary first functional group with the second functional group via a biomacromolecule induced click chemistry reaction to form the candidate imaging probe; f) isolating and identifying the candidate imaging probe; g) preparing the candidate imaging probe by chemical synthesis; and h) for imaging applications, converting the candidate imaging probe into an imaging probe.

  本发明提供了一种识别候选成像探针的方法，该方法包括：a）将第一组候选化合物与目标生物大分子接触；b）从第一组中识别出对第一结合位点具有亲和力的第一成员；c）将从第一组中识别出的第一成员与目标生物大分子接触；d）将第二组候选化合物与第一成员和目标生物大分子接触；e）通过生物大分子诱导的点击化学反应，使互补的第一功能团与第二功能团反应，形成候选成像探针；f）分离和鉴定候选成像探针；g）通过化学合成制备候选成像探针；h）将候选成像探针转化为成像探针，用于成像应用。
• THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
  申请人：Popovici-Muller Janeta

  公开号：US20130184222A1

  公开（公告）日：2013-07-18

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.

  提供了一种治疗癌症的方法，其特征在于存在IDH1基因突变等位基因，包括向需要此类治疗的受试者施用此处所述的化合物。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：CHATTERJEE Arnab Kumar

  公开号：US20150291598A1

  公开（公告）日：2015-10-15

  The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.

  本发明提供了I式化合物：[插入公式]或其药学上可接受的盐、互变异构体或立体异构体，其中变量的定义如本文所述。本发明还提供了包含这种化合物的药物组合物以及使用这种化合物治疗、预防、抑制、改善或根除由疟原虫引起的疾病，如疟疾的病理学和/或症状学的方法。